Equity Profile

HALO

Halozyme Therapeutics, Inc.

Health CareBiotechnology$11.4B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing therapies for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$1.82

Revenue

Revenue growth reflects the company's ability to expand its market presence and meet demand for its products.

$402M

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing therapies for patients with serious diseases. With a market cap of $11 billion, it operates in the health care sector, aiming to improve treatment options through innovative drug delivery technologies.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q1 2026, Halozyme reported an EPS of $1.60, exceeding expectations by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Continue to focus on expanding product offerings.
Enhance partnerships to drive revenue growth.
Maintain cost management to improve profitability.

Expectations

Wall Street Expectations

Analysts expect Halozyme to report solid earnings this quarter, with a consensus EPS of $1.82 and revenue of $402 million. Investors are keen to see if the company can maintain its momentum from the previous quarter.

Bull Case

If Halozyme beats earnings expectations, it could signal strong demand for its products and effective cost management, potentially driving the stock higher.

Bear Case

Conversely, if the company misses its targets or provides weak guidance, it may raise concerns about its growth prospects and lead to a decline in stock price.

Key Metrics to Watch

EPS

$1.82

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$402M

Revenue growth reflects the company's ability to expand its market presence and meet demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.82?

A beat on EPS would reinforce confidence in the company's profitability and growth trajectory.

What guidance will management provide for future revenue growth?

Future revenue guidance will be crucial for assessing the company's growth outlook and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Halozyme's ability to exceed EPS expectations due to its recent strong performance and effective cost management.

Supporting Evidence

Halozyme has consistently beaten EPS estimates, with an 88% beat rate over the last eight quarters.

The company's recent focus on expanding product offerings could drive revenue growth beyond current expectations.

Key Risk

If management provides strong guidance for future revenue growth, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Halozyme can sustain its recent momentum and meet or exceed analyst expectations.

Bull Confirmed If

An EPS of $1.85 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.75 would support the bear case, suggesting potential challenges in revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move, suggesting investors are anticipating volatility around the earnings announcement.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests a potential stock increase of around +0.49%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of around +1.31% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on cost management strategies and their effect on profitability.
3Management's outlook on market conditions and competitive landscape.
4Insights into partnerships or collaborations that could enhance growth.
5Any changes in guidance for future quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing therapies for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

$1.82

Revenue

Revenue growth reflects the company's ability to expand its market presence and meet demand for its products.

$402M

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q1 2026, Halozyme reported an EPS of $1.60, exceeding expectations by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Continue to focus on expanding product offerings.
Enhance partnerships to drive revenue growth.
Maintain cost management to improve profitability.

Expectations

Wall Street Expectations

Bull Case

If Halozyme beats earnings expectations, it could signal strong demand for its products and effective cost management, potentially driving the stock higher.

Bear Case

Conversely, if the company misses its targets or provides weak guidance, it may raise concerns about its growth prospects and lead to a decline in stock price.

Key Metrics to Watch

EPS

$1.82

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.

Revenue

$402M

Revenue growth reflects the company's ability to expand its market presence and meet demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $1.82?

A beat on EPS would reinforce confidence in the company's profitability and growth trajectory.

What guidance will management provide for future revenue growth?

Future revenue guidance will be crucial for assessing the company's growth outlook and investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Halozyme's ability to exceed EPS expectations due to its recent strong performance and effective cost management.

Supporting Evidence

Halozyme has consistently beaten EPS estimates, with an 88% beat rate over the last eight quarters.

The company's recent focus on expanding product offerings could drive revenue growth beyond current expectations.

Key Risk

If management provides strong guidance for future revenue growth, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on whether Halozyme can sustain its recent momentum and meet or exceed analyst expectations.

Bull Confirmed If

An EPS of $1.85 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.75 would support the bear case, suggesting potential challenges in revenue generation.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move, suggesting investors are anticipating volatility around the earnings announcement.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests a potential stock increase of around +0.49%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of around +1.31% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on cost management strategies and their effect on profitability.
3Management's outlook on market conditions and competitive landscape.
4Insights into partnerships or collaborations that could enhance growth.
5Any changes in guidance for future quarters.